Cyp17, urinary sex steroid levels and breast cancer risk in postmenopausal women

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 4, 2005, Pages 815-820

  Onland Moret, N Charlotte ^a   Van Gils, Carla H ^a   Roest, Mark ^a   Grobbee, Diederick E ^a   Peeters, Petra H M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANEDIOL; CREATININE; CYTOCHROME P450 17; ESTRADIOL; ESTRONE; SEX HORMONE; TESTOSTERONE;

ADULT; AGED; ALLELE; ARTICLE; BODY MASS; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENOTYPE; GEOMETRY; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZATION; STEROID URINE LEVEL; URINE;

ADULT; AGED; BODY MASS INDEX; BREAST NEOPLASMS; FEMALE; GENOTYPE; GONADAL STEROID HORMONES; HUMANS; INCIDENCE; MIDDLE AGED; NETHERLANDS; POPULATION SURVEILLANCE; POSTMENOPAUSE; RISK FACTORS; STEROID 17-ALPHA-HYDROXYLASE;

EID: 16444381765     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-04-0197     Document Type: Article

References (40)

1. The Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-16.
2. Onland-Moret NC, Kaaks R, van Noord PA, et al. Urinary endogenous sex hormone levels and the risk of postmenopausal breast cancer. Br J Cancer 2003;88:1394-9.
3. Picado-Leonard J, Miller WL. Cloning and sequence of the human gene for P450c17 (steroid 17 α-hydroxylase/17,20 lyase): similarity with the gene for P450c21. DNA 1987;6:439-48.
4. Carey AH, Waterworth D, Patel K, et al. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 1994;3:1873-6.
5. Kristensen VN, Haraldsen EK, Anderson KB, et al. CYP17 and breast cancer risk: the polymorphism in the 5′ flanking area of the gene does not influence binding to Sp-1. Cancer Res 1999;59:2825-8.
6. Feigelson HS, Coetzee GA, Kolonel LN, Ross RK, Henderson BE. A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res 1997;57:1063-5.
7. Dunning AM, Healey CS, Pharoah PD, et al. No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer. Br J Cancer 1998;77:2045-7.
8. Weston A, Pan CF, Bleiweiss IJ, et al. CYP17 genotype and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1998;7:941-4.
9. Helzlsouer KJ, Huang HY, Strickland PT, et al. Association between CYP17 polymorphisms and the development of breast cancer. Cancer Epidemiol Biomarkers Prev 1998;7:945-9.
10. Haiman CA, Hankinson SE, Spiegelman D, et al. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res 1999;59:1015-20.
11. Bergman-Jungestrom M, Gentile M, Lundin AC, Wingren S. Association between CYP17 gene polymorphism and risk of breast cancer in young women. Int J Cancer 1999;84:350-3.
12. Huang CS, Chern HD, Chang KJ, Cheng CW, Hsu SM, Shen CY. Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res 1999;59:4870-5.
13. Mitrunen K, Jourenkova N, Kataja V, et al. Steroid metabolism gene CYP17 polymorphism and the development of breast cancer. Cancer Epidemiol Biomarkers Prev 2000;9:1343-8.
14. Miyoshi Y, Iwao K, Ikeda N, Egawa C, Noguchi S. Generic polymorphism in CYP17 and breast cancer risk in Japanese women. Eur J Cancer 2000;36:2375-9.
15. Spurdle AB, Hopper JL, Dite GS, et al. CYP17 promoter polymorphism and breast cancer in Australian women under age forty years. J Natl Cancer Inst 2000;92:1674-81.
16. Feigelson HS, McKean-Cowdin R, Coetzee GA, Stram DO, Kolonel LN, Henderson BE. Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates. Cancer Res 2001;61:785-9.
17. Gudmundsdotrir K, Thorlacius S, Jonasson JG, Sigfusson BF, Tryggvadottir L, Eyfjord JE. CYP17 promoter polymorphism and breast cancer risk in males and females in relation to BRCA2 status. Br J Cancer 2003;88:933-6.
18. Ambrosone CB, Moysich KB, Furberg H, et al. CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors. Breast Cancer Res 2003;5:R45-51.
19. Wu AH, Seow A, Arakawa K, Van Den BD, Lee HP, Yu MC. HSD17B1 and CYP17 polymorphisms and breast cancer risk among Chinese women in Singapore. Int J Cancer 2003;104:450-7.
20. Gharani N, Waterworth DM, Williamson R, Franks S. 5′ Polymorphism of the CYP17 gene is not associated with serum testosterone levels in women with polycystic ovaries. J Clin Endocrinol Metab 1996;81:4174.
21. Feigelson HS, Shames LS, Pike MC, Coetzee GA, Stanczyk FZ, Henderson BE. Cytochrome P450c17α gene (CYP27) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res 1998;58:585-7.
22. Haiman CA, Stampfer MJ, Giovannucci E, et al. The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer. Cancer Epidemiol Biomarkers Prev 2001;10:743-8.
23. Allen NE, Forrest MS, Key TJ. The association between polymorphisms in the CYP17 and 5α-reductase (SRD5A2) genes and serum androgen concentrations in men. Cancer Epidemiol Biomarkers Prev 2001;10:185-9.
24. Zmuda JM, Cauley JA, Kuller LH, Ferrell RE. A common promotor variant in the cytochrome P450c17α (CYP27) gene is associated with bioavailability testosterone levels and bone size in men. J Bone Miner Res 2001;16:911-7.
25. Garcia-Closas M, Herbstman J, Schiffman M, Glass A, Dorgan JF. Relationship between serum hormone concentrations, reproductive history, alcohol consumption and genetic polymorphisms in pre-menopausal women. Int J Cancer 2002;102:172-8.
26. Jernstrom H, Vesprini D, Bradlow HL, Narod SA. Re: CYP17 promoter polymorphism and breast cancer in Australian women under age forty years. J Natl Cancer Inst 2001;93:554-5.
27. Lukanova A, Lundin E, Zeleniuch-Jacquotte A, et al. Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. Eur J Endocrinol 2004;150:161-71.
28. Randolph JF Jr, Sowers M, Gold EB, et al. Reproductive hormones in the early menopausal transition: relationship to ethnicity, body size, and menopausal status. J Clin Endocrinol Metab 2003;88:1516-22.
29. Trichopoulos D, Yen S, Brown J, Cole P, MacMahon B. The effect of westernization on urine estrogens, frequency of ovulation, and breast cancer risk. A study of ethnic Chinese women in the Orient and the USA. Cancer 1984;53:187-92.
30. de Waard F, Collette HJ, Rombach JJ, Baanders-van Halewijn EA, Honing C. The DOM project for the early detection of breast cancer, Utrecht, the Netherlands. J Chronic Dis 1984;37:1-44.
31. Elias SG, Peelers PH, Grobbee DE, van Noord PA. Breast cancer risk after caloric restriction during the 1944-1945 Dutch famine. J Natl Cancer Inst 2004;96:539-46.
32. van der Hel OL, van der Luijt RB, Bueno de Mesquita HB, et al. Quality and quantity of DNA isolated from frozen urine in population-based research. Anal Biochem 2002;304:206-11.
33. Rinaldi S, Onland-Moret NC, Kaaks R, et al. Reproducibility over time of measurements of androgens, estrogens and hydroxy estrogens in urine samples from post-menopausal women. Eur J Epidemiol 2003;18:417-24.
34. Barlow WE, Ichikawa L, Rosner D, Izumi S. Analysis of case-cohort designs. J Clin Epidemiol 1999;52:1165-72.
35. Ye Z, Parry JM. The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis. Mutagenesis 2002;17:119-26.
36. Haiman CA, Hankinson SE, Colditz GA, Hunter DJ, De V. I A polymorphism in CYP17 and endometrial cancer risk. Cancer Res 2001;61:3955-60.
37. Somner J, McLellan S, Cheung J, et al. Polymorphisms in the P450 c17 (17-hydroxylase/17,20-lyase) and P450 c19 (aromatase) genes: association with serum sex steroid concentrations and bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2004;89:344-51.
38. Cauley JA, Gutai JP, Kuller LH, LeDonne D, Powell JG. The epidemiology of serum sex hormones in postmenopausal women. Am J Epidemiol 1989;129:1120-31.
39. Madigan MP, Troisi R, Potischman N, Dorgan JF, Brinton LA, Hoover RN. Serum hormone levels in relation to reproductive and lifestyle factors in postmenopausal women (United States). Cancer Causes Control 1998;9:199-207.
40. Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis 2000;21:427-33.